Pre-market Hot Trades in US Stocks
uniQure is up 6.32% in pre-market trading. Based on recent important news:
<ol>
<li>
On September 24, uniQure announced that its experimental gene therapy significantly slowed the progression of Huntington's disease in early to mid-stage trials, leading to a substantial increase in stock price. The therapy reduced disease progression by 75% over 36 months, driving the stock price up approximately 248%. Data source: company announcement.
</li>
<li>
On September 25, uniQure launched a $200 million public offering, including common stock and pre-funded warrants, to support the potential U.S. market launch of its AMT-130. This move enhances the company's financial flexibility. Data source: company announcement.
</li>
<li>
On September 25, Stifel raised uniQure's target price from $30 to $65, reflecting market confidence in its future prospects. Data source: analyst report. The gene therapy industry is performing strongly, with significant capital inflows.
</li>
</ol>
Top Gainers in Pre-market US Stocks
PepGen is up 99.62% in pre-market trading. Based on recent key news:
<ol>
<li>
On September 25, PepGen announced a $100 million public offering at a price of $3.20 per share, driving the stock price up. This move aims to fund its research and clinical trials. Data source: Reuters.
</li>
<li>
On September 24, PepGen released positive clinical data from its FREEDOM-DM1 study, showing an average splice correction rate of 53.7%, boosting market confidence. Data source: PepGen Inc.
</li>
<li>
On September 25, Guggenheim reiterated its buy rating on PepGen and maintained a target price of $6, further supporting the stock price increase. Data source: Guggenheim. The biotechnology sector has recently performed strongly, with significant capital inflows
</li>
</ol>

YAAS

QURE

Youxin Tech pre-market down 8.66%; uniQure pre-market up 6.32%; PepGen pre-market up 99.62%; WORK Medical Tech pre-market up 53.16%; OFA pre-market up 40.60%

Pre-market hot trades in US stocks: Youxin Tech pre-market down 8.66%; uniQure pre-market up 6.32%